Harmony of operations of some vitamins in controlling the 2019-nCoV virus based on scientific reports -

Document Type : Review Article


1 Department of Chemistry, Qaemshahr Branch, Islamic Azad University, Qaemshahr, Iran

2 Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran

3 Department of Environmental Health, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran

4 Department of Chemistry, Payame Noor University, Tehran, Iran

5 R&D Department, Quality Control Laboratories, Tofigh Daru Research and Engineering Company, Tehran, Iran


Unlike other related compounds, vitamin D has multi-function operations against 2019-nCoV virus via intervention in several parts of its lifecycle. In one hand, this compound induces antimicrobial peptides like cathelicidins and proteins like defensins that lead to lower viral replication rates and also reduces the concentrations of pro-inflammatory cytokines (it causes inflammation that results in multi-organ failure). In the other hand, a vitamin D agonist, calcitriol, modulates the expression of members of the renin‑angiotensin system, including angiotensin converting enzymes like ACE2 (the cell receptor for 2019-nCoV viral spike protein). Thus, vitamin D may reduce the spike rate of the virus to the lung cells, resulting in inhibition of the virus in entry stage. About vitamin B series, there is a report that claims vitamin B12 may inhibit RNA-dependent-RNA polymerase activity of nsp12 from the 2019-nCoV virus.‏
Also, vitamins C, and E (anti-oxidants with anti-inflammatory effects) could be effective in inhibiting the damages of the organs caused by the acute immune response (inhibiting the release of high concentrations of free radicals) during COVID-19 as well as boosting the human immune system. It must be mentioned that, in spite of the presented supporting references, this paper is prepared for researcher, not for all people.


[1] R. H. Britten, The incidence of epidemic influenza, 1918-19. Public. Health. Rep., 47 (1932) 304-339.‏
[2] Y. S. Malik, S. Sircar, S. Bhat, K. Sharun, K. Dhama, M. Dadar, W. Chaicumpa, Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments. Vet. Q., 40 (2020) 68-76.‏
[3] M. A. Alamri, M. T. Qamar, S. F. Alqahtani, Pharmacoinformatics and molecular dynamic simulation studies reveal potential inhibitors of SARS-CoV-2 main protease 3CLpro. Preprints (2020) DOI: 10.20944/preprints202002.0308.v1.
[4] K. Bagherzadeh, K. Daneshvarnejad, M. Abbasinazari, In silico Repositioning for Dual Inhibitor Discovery of SARS-CoV-2 (COVID-19) 3C-like Protease and Papain-like Peptidase. Preprints (2020) DOI: 10.20944/preprints202004.0084.v1
[5] V. Yethindra, Role of GS-5734 (Remdesivir) in inhibiting SARS-CoV and MERS-CoV: The expected role of GS-5734 (Remdesivir) in COVID-19 (2019-nCoV)-VYTR hypothesis. Int. J. Pharm. Sci. Res., 11 (2020) 1-6.‏
[6] L. Dong, S. Hu, J. Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug. Discov. Ther., 14 (2020) 58-60. ‏
[7] a) S. A. Siadati, M. Afzali, M. Sayyadi, Could silver nano-particles control the 2019-nCoV virus?; An urgent glance to the past. Chem. Rev. Lett., 3 (2020) 9-11.
b) O.. Zachar, Formulations for COVID-19 Early Stage Treatment via Silver Nanoparticles Inhalation Delivery at Home and Hospital. ScienceOpen Preprints., (2020) ‏DOI: 10.14293/S2199-1006.1.SOR-.PPHBJEO.v1;
c) M. Patel, Antimicrobial Paper Embedded with Nanoparticles as Spread-Breaker for Corona Virus. Virus., 3 (2020) 001-012.‏
d) M. Patel, Nanoparticle-based antimicrobial paper as spread-breaker for corona virus. Paper. Technol. Int., 62 (2020) 62, 20-25.‏
[8] A. Casadevall, L. A. Pirofski, The convalescent sera option for containing COVID-19. 130 (2020)1545-1548.‏
[9] N. Narayanan, D. T. Nair, Vitamin B12 May Inhibit RNA-Dependent-RNA Polymerase Activity of nsp12 from the COVID-19. Virus. Preprints., (2020) DOI: 10.20944/preprints202003.0347.v1.
[10] [10] R. Jayawardena, P. Sooriyaarachchi, M. Chourdakis, C. Jeewandara, P. Ranasinghe, Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. Diabetes. Metab. Syndr., 14 (2020) 367-382.
[11] S. Roy, A. Awasthi, Vitamin A and the Immune System. In Nutrition and Immunity, Cham., 55 (2019) 53-73.
[12] C. Stephensen, Z. Moldoveanu, N. N. Gangopadhyay, Vitamin A deficiency diminishes the salivary immunoglobulin A response and enhances the serum immunoglobulin G response to influenza A virus infection in BALB/c. mice. J. Nutr., 126 (1996) 94-102.
[13] Z. Y. Peng, Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial.
https://clinicaltrials.gov/ct2/show/NCT04264533, phase 2 of
clinical trial (2020).
[14] R. Gupta, A. Ghosh, A. K. Singh, A. Misra, Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabete. Metab. Syndr., 14 (2020) 211-212.
[15] A. Erol, High-dose Intravenous Vitamin C Treatment for COVID-19–A Medical Discussion. BMJ. Open., 10 (2020) DOI: 10.1136/bmjopen-2020-039519.
[16] World Health Organization. WHO R&D Blueprint: informal consultation on prioritization of candidate therapeutic agents for use in novel coronavirus 2019 infection, Geneva, Switzerland, 24 January 2020 (No. WHO/HEO/R&D Blueprint (‎‎nCoV)‎‎/2020.1). World Health Organization.
[17] L. S. Wang, Y. R. Wang, D. W. Ye, Q. Q. Liu, A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int. J. Antimicrob. Agents., 55 (2020) 105948. [19] [19] L. Zhang, Y. Liu, Potential interventions for novel coronavirus in China: a systemic review. J. Med. Virol., 92 (2020) 479-490.
[18] M. Hoffmann, H. Kleine-Weber, N. Krüger, M. A. Mueller, C. Drosten, S. Pöhlmann, The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. (2020) DOI:10.1101/2020.01.31.929042.
[19] J. Xu, J. Yang, J. Chen, Q. Luo, Q. Zhang, H. Zhang, Vitamin D alleviates lipopolysaccharide‑induced acute lung injury via regulation of the renin‑angiotensin system. Res. Mol. Med., 16 (2017) 7432-7438.‏
[20] W. B. Grant, H. Lahore, S. L. McDonnell, C. A. Baggerly, C. B. French, J. L. Aliano, H. P. Bhattoa, Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients., 12 (2020) 988.‏
[21] Ilie PC, Stefanescu S, Smith L. The role of Vitamin D in the prevention of Coronavirus Disease 2019 infection and mortality. (2020) DOI:10.21203/rs.3.rs-21211/v1.
[22] M. Braiman, Latitude Dependence of the COVID-19 Mortality Rate—A Possible Relationship to Vitamin D Deficiency?.Available at SSRN 3561958.‏ (2020) DOI: 10.2139/ssrn.3561958.
[23] M. Alipio, Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-2019). Available at SSRN 3571484.‏ (2020) DOI:10.2139/ssrn.3571484 .
[24] H. Hemila, Vitamin C intake and susceptibility to pneumonia. Pediatr. Infect. Dis. J., 16 (1997) 836-837.
[25] D. M. McCartney, D. G. Byrne, Optimisation of Vitamin D Status for Enhanced Immuno-protection Against Covid-19. Ir. J. Med. Sci., 113 (2020) 58-58.‏
[26] M. Heinonen, V. Piironen, The tocopherol, tocotrienol, and vitamin E content of the average Finnish diet. Int. J. Vit. Nutr. Res., 61 (1991)27-32.
[27] J. Z. Wang, R. Y. Zhang, J. Bai, An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients. Int. J. Cardiol., (2020) Doi: 10.1016/j.ijcard.2020.04.009.
[28] N. Erol, L. Saglam, Y. S. Saglam, H. S. Erol, S. Altun, M. S. Aktas, The protection potential of antioxidant vitamins against acute respiratory distress syndrome: a rat trial. Inflammation., 42 (2019)1585–1594.
[29] P. K. Law, Emergent Serum Therapy and Antibody Medicine to Counteract Sudden Attacks of COVID-19 and Other Pathogenic Epidemics, Open. J. Regen. Med., 9 (2020) 1-7.
[30] A. Fischer, G. Rimbach, Gene Regulatory Activity of Vitamin E. Vit. E. Human. Health., (2019) 81-98.
Volume 3, Issue 4 - Serial Number 4
October 2020
Pages 202-206
  • Receive Date: 01 October 2020
  • Revise Date: 17 November 2020
  • Accept Date: 01 October 2020
  • First Publish Date: 01 October 2020